Logo image of ARTL

ARTELO BIOSCIENCES INC (ARTL) Stock Fundamental Analysis

NASDAQ:ARTL - Nasdaq - US04301G5080 - Common Stock - Currency: USD

14.87  +0.7 (+4.94%)

Fundamental Rating

2

Taking everything into account, ARTL scores 2 out of 10 in our fundamental rating. ARTL was compared to 194 industry peers in the Pharmaceuticals industry. While ARTL seems to be doing ok healthwise, there are quite some concerns on its profitability. ARTL has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ARTL had negative earnings in the past year.
ARTL had a negative operating cash flow in the past year.
In the past 5 years ARTL always reported negative net income.
ARTL had a negative operating cash flow in each of the past 5 years.
ARTL Yearly Net Income VS EBIT VS OCF VS FCFARTL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

The Return On Assets of ARTL (-276.30%) is worse than 93.81% of its industry peers.
ARTL has a worse Return On Equity (-1489.57%) than 81.96% of its industry peers.
Industry RankSector Rank
ROA -276.3%
ROE -1489.57%
ROIC N/A
ROA(3y)-109.94%
ROA(5y)-98.97%
ROE(3y)-158.36%
ROE(5y)-131.4%
ROIC(3y)N/A
ROIC(5y)N/A
ARTL Yearly ROA, ROE, ROICARTL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K 1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ARTL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARTL Yearly Profit, Operating, Gross MarginsARTL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

4

2. Health

2.1 Basic Checks

ARTL has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ARTL has been increased compared to 5 years ago.
There is no outstanding debt for ARTL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ARTL Yearly Shares OutstandingARTL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
ARTL Yearly Total Debt VS Total AssetsARTL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of -29.06, we must say that ARTL is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of ARTL (-29.06) is worse than 84.02% of its industry peers.
ARTL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -29.06
ROIC/WACCN/A
WACCN/A
ARTL Yearly LT Debt VS Equity VS FCFARTL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M 15M

2.3 Liquidity

ARTL has a Current Ratio of 0.49. This is a bad value and indicates that ARTL is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of ARTL (0.49) is worse than 93.30% of its industry peers.
A Quick Ratio of 0.49 indicates that ARTL may have some problems paying its short term obligations.
ARTL has a worse Quick ratio (0.49) than 91.24% of its industry peers.
Industry RankSector Rank
Current Ratio 0.49
Quick Ratio 0.49
ARTL Yearly Current Assets VS Current LiabilitesARTL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 6.85% over the past year.
EPS 1Y (TTM)6.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.69%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 14.98% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y51.17%
EPS Next 2Y35.13%
EPS Next 3Y23.04%
EPS Next 5Y14.98%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ARTL Yearly Revenue VS EstimatesARTL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 2030 2031 2032 100M 200M 300M 400M 500M
ARTL Yearly EPS VS EstimatesARTL Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 -10 -20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ARTL. In the last year negative earnings were reported.
Also next year ARTL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ARTL Price Earnings VS Forward Price EarningsARTL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ARTL Per share dataARTL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15

4.3 Compensation for Growth

A more expensive valuation may be justified as ARTL's earnings are expected to grow with 23.04% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.13%
EPS Next 3Y23.04%

More info and screens

0

5. Dividend

5.1 Amount

ARTL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARTELO BIOSCIENCES INC

NASDAQ:ARTL (7/23/2025, 10:16:18 AM)

14.87

+0.7 (+4.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)08-11 2025-08-11
Inst Owners2.72%
Inst Owner Change0%
Ins Owners0.81%
Ins Owner Change0%
Market Cap8.18M
Analysts82.22
Price Target30.6 (105.78%)
Short Float %N/A
Short Ratio0.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-302.83%
Min EPS beat(2)-442.99%
Max EPS beat(2)-162.68%
EPS beat(4)2
Avg EPS beat(4)-141.64%
Min EPS beat(4)-442.99%
Max EPS beat(4)25.94%
EPS beat(8)4
Avg EPS beat(8)-76.93%
EPS beat(12)6
Avg EPS beat(12)-53.82%
EPS beat(16)9
Avg EPS beat(16)-31.98%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)445.46%
PT rev (3m)462.5%
EPS NQ rev (1m)-500%
EPS NQ rev (3m)-500%
EPS NY rev (1m)-25.86%
EPS NY rev (3m)-655.17%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 12.54
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-17.94
EYN/A
EPS(NY)-3.18
Fwd EYN/A
FCF(TTM)-12.74
FCFYN/A
OCF(TTM)-12.74
OCFYN/A
SpS0
BVpS1.19
TBVpS-2.52
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -276.3%
ROE -1489.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-109.94%
ROA(5y)-98.97%
ROE(3y)-158.36%
ROE(5y)-131.4%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.49
Quick Ratio 0.49
Altman-Z -29.06
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.69%
EPS Next Y51.17%
EPS Next 2Y35.13%
EPS Next 3Y23.04%
EPS Next 5Y14.98%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y3.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y14.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y14.02%
OCF growth 3YN/A
OCF growth 5YN/A